Lightstone Ventures

Dedicated to empowering entrepreneurs with the resources and guidance needed to bring their innovative therapeutics to patients.

[Lightstone Ventures @LightstoneVC]

Congrats to @Tagworkspharma on this significant milestone! Great news for patients as the Company enters clinical development of their Phase 1 trial of TGW101, a first-in-class antibody drug-conjugate targeting tumor associated glycoprotein 72 (TAG-72) in advanced #solidtumors.

[Tagworks Pharmaceuticals @Tagworkspharma]

We’re thrilled to announce the initiation of our Phase 1 clinical trial evaluating TGW101, an #ADC developed with our Click-to-Release treatment platform, in patients with advanced #solidtumors. Learn more: https://t.co/EKirGtjYvH

[Lightstone Ventures @LightstoneVC]

Please join us in welcoming H. Martin Seidel, Ph.D., to the Lightstone team as Advisor. Dr. Seidel brings over 30 years of experience across R&D and Business Development in both pharma and biotech to our team. We look forward to working with you!

[Lightstone Ventures @LightstoneVC]

Congratulations to Brendan Kelly, PhD, on his promotion to Principal at Lightstone Ventures! As a core member of our investment team, we celebrate Brendan’s leadership and contributions across our portfolio. We look forward to continuing our exciting work together!

[Lightstone Ventures @LightstoneVC]

We welcome Ken Mills as CEO and member of the Board of Directors for @tagworkspharma as the company expects to embark on its next phase of growth and enter the clinic in 2025 with its lead antibody-drug conjugate program, TGW101.

[Tagworks Pharmaceuticals @Tagworkspharma]

We're excited to announce Ken Mills has been appointed our new CEO and that Marc Robillard will continue as CSO & Board member. We look forward to working to bring our Click-to-Release platform and lead ADC program for solid tumors into the clinic in 2025. https://t.co/RFcVYuXonc

[Lightstone Ventures @LightstoneVC]

Lightstone portfolio company @VoltaMedical announced positive results from their TAILORED-AF trial, comparing AI-assisted ablation procedure with the conventional treatment for persistent atrial fibrillation patients. Learn more about what was presented: https://t.co/or6t4h07qJ

[Lightstone Ventures @LightstoneVC]

Congrats to @cerevance, who announced the closing of their Series B-1 Extension financing round. Lightstone is a proud fund partner, and we look forward to company updates as they progress their pipeline of therapies for CNS diseases. Read more: https://t.co/auNnWT2pUK

[Cerevance @cerevance]

We’re pleased to announce the addition of $47M to our Series B-1 Extension to advance our CVN424 therapy for the treatment of PD into a Phase 3 clinical trial and to support our robust pipeline of CNS treatments. Read more here: https://t.co/g2lusRBeVy

[Lightstone Ventures @LightstoneVC]

Welcome José-Alain Sahel, M.D., to Lightstone, joining us as an advisor. A distinguished professor and leader in the Ophthalmology and Neuroscience space, Dr. Sahel’s deep knowledge will play a key role in supporting new and existing portfolio companies.

[Lightstone Ventures @LightstoneVC]

Congratulations to Jingjing Wang, Ph.D. on her promotion to Vice President at Lightstone! As a core member of our investment team, we look forward to exciting things to come as we continue our work together.

[Lightstone Ventures @LightstoneVC]

Congratulations to @RelievantMed, that has developed and commercialized the Intracept® Procedure, their FDA-cleared treatment for chronic #vertebrogenic pain, on being acquired by @bostonsci! Great news and great for patients. Learn more here: https://t.co/LyaPkMvFGg

[Intracept by Boston Scientific @RelievantMed]

Relievant is now Boston Scientific. Follow @bostonsci to stay up to date as we advance pain management solutions as part of Neuromodulation at Boston Scientific. Learn more here: https://t.co/pJdgSirxhx

[Lightstone Ventures @LightstoneVC]

Exciting news from @cerevance, who dosed the first patient in their ASCEND Phase 2 clinical study of CVN424 for the treatment of individuals with Parkinson’s Disease. We look forward to future updates! Full press release: https://t.co/MZWZlScfsS

[Cerevance @cerevance]

https://t.co/Lef4l2muyu

[Lightstone Ventures @LightstoneVC]

Today, the launch of 65LAB was announced, a company creation vehicle designed to advance drug discovery & new therapeutics companies in Singapore. As a proud founding partner, we look forward to the potential patient impact of these discoveries. Read more: https://t.co/nmvRfSb4OG

[Lightstone Ventures @LightstoneVC]

Today, @AlxOncology shared encouraging positive interim Phase 2 data from their ASPEN-06 clinical trial evaluating evorpacept, for the treatment of advanced HER2-positive gastric cancer. Full press release here: https://t.co/iy8tMEhh0x

[ALX Oncology @AlxOncology]

ALX Oncology today announced positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial: https://t.co/l4n9sglwti

[Lightstone Ventures @LightstoneVC]

Sharing an exciting update from @cerevance, who recently announced that the first patient has been dosed in their Phase 1 study evaluating safety and tolerability of CVN293, for the treatment of #ALS and #Alzheimers. Full press release: https://t.co/ze8zWxEixj

[Cerevance @cerevance]

We’re pleased to announce that the first subject has been dosed in our Phase 1 clinical study evaluating CVN293, a selective inhibitor designed to modulate neuroinflammation for the treatment of ALS and Alzheimer’s disease. Read the release to learn more: https://t.co/rEw9uGUTPa

[Lightstone Ventures @LightstoneVC]

Congrats @RelievantMed, whose agreement to be acquired by @bostonsci was announced. The company’s therapy, the Intracept® Procedure, is their FDA-cleared treatment for chronic #vertebrogenic pain. Great news and great for patients! Learn more here: https://t.co/Ajyd0TPjva

[Lightstone Ventures @LightstoneVC]

Congratulations to @NimbusTx, on the closing of their $210 million private financing! Lightstone is a proud fund partner, and we look forward to updates as the company advances their pipeline in immunology, cancer and metabolic disease. Learn more: https://t.co/8uTPuOj6Us

[Nimbus Therapeutics @NimbusTx]

We’re excited to announce a $210 million private financing to advance our next wave of tech-enabled small molecule medicines. Learn more: https://t.co/9fzwrp8KvA

[Lightstone Ventures @LightstoneVC]

Congrats to @Cerevance for being named one of @FierceBiotech’s 2023 #Fierce15 biotech companies. We’re looking forward to seeing more great accomplishments from Cerevance in the future!

[Cerevance @cerevance]

We’re thrilled to announce that @FierceBiotech has named us a #Fierce15 biotech company of 2023. It is an honor to be acknowledged within this outstanding array of industry experts, and a testament to the groundbreaking work we are doing at Cerevance: https://t.co/EuHXALwxCv

[Lightstone Ventures @LightstoneVC]

Congrats to @FIRE1_HF on successfully implanting the first U.S. patients with its FIRE1™ System for remote heart failure monitoring in a study that will assess the Company’s technology to improve outcomes for heart failure patients. Learn more: https://t.co/cbWZ3LrjFC

[FIRE1 @FIRE1_HF]

We are in the US! Another great milestone for the FIRE1 team in its mission to help people with heart failure live their normal lives, thanks to all our docs across the US for making this happen and our National PI @NirUrielMD

https://t.co/HzHIWRFeOe

[Lightstone Ventures @LightstoneVC]

Congrats to @Tagworkspharma, on the closing of their Series A financing! Lightstone is a proud fund partner, and we look forward to updates as the company advances their lead ADC program, TGW101, and their proprietary Click-to-Release platform. Learn more: https://t.co/6C2DQyl3ND

[Tagworks Pharmaceuticals @Tagworkspharma]

We’re excited to announce that we’ve raised $65 Million in Series A financing to advance a pipeline of Click-to-Release Therapeutics ! https://t.co/TKTHHZVGLy

[Lightstone Ventures @LightstoneVC]

Lightstone portfolio company, @RelievantMed, recently announced the publication of three-year pooled results from the #Intracept Procedure, demonstrating long-term pain relief and reduced opioid use for patients with vertebrogenic pain. Learn more: https://t.co/knPKQqAUwy

[Intracept by Boston Scientific @RelievantMed]

A new study in Interventional Pain Medicine details 3-year pooled outcomes from the #Intracept Procedure that demonstrate long-term pain relief and reduced opioid use in chronic #vertebrogenic low back pain patients. Read our press release to learn more: https://t.co/6owRTQhCRM

[Lightstone Ventures @LightstoneVC]

This Thursday at #BIO2023, Lightstone Partner Christina Isacson, will discuss the role of health systems within the commercialization of new therapies alongside fellow industry experts. Panel details here: https://t.co/NcmHlMS6Xo